Verition Fund Management
CSTL icon

Verition Fund Management’s Castle Biosciences CSTL Stock Holding History

Verition Fund Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,811
Closed -$654K – 2548
2025
Q4 		$654K Buy
16,811
+1,169
+7% +$37.7K ﹤0.01% 2466
2025
Q3 		$356K Sell
15,642
-15,897
-50% -$323K ﹤0.01% 3213
2025
Q2 		$644K Buy
31,539
+868
+3% +$16.1K ﹤0.01% 2778
2025
Q1 		$614K Buy
30,671
+21,623
+239% +$535K ﹤0.01% 2449
2024
Q4 		$241K Buy
+9,048
New +$276K ﹤0.01% 2890
2023
Q4 		– Sell
-12,942
Closed -$219K – 2393
2023
Q3 		$219K Sell
12,942
-4,700
-27% -$82.2K ﹤0.01% 1929
2023
Q2 		$242K Buy
+17,642
New +$357K ﹤0.01% 1720

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's CSTL Position: Q1 2026 in Review

Verition Fund Management sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 16,811 shares — an estimated $654K sold.

Verition Fund Management first reported a position in CSTL in Q2 2023 and held it in 7 quarters. The position peaked at $654K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Verition Fund Management reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 16,811 Castle Biosciences shares in Q1 2026, an estimated $654K.
  • Verition Fund Management first reported a position in Castle Biosciences in Q2 2023 and held it in 7 quarters.
  • Verition Fund Management's Castle Biosciences position peaked at $654K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.